GT200500315A - Formas de dosificacion oral solidas que contienen una dosis baja de estradiol - Google Patents

Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Info

Publication number
GT200500315A
GT200500315A GT200500315A GT200500315A GT200500315A GT 200500315 A GT200500315 A GT 200500315A GT 200500315 A GT200500315 A GT 200500315A GT 200500315 A GT200500315 A GT 200500315A GT 200500315 A GT200500315 A GT 200500315A
Authority
GT
Guatemala
Prior art keywords
dosage forms
solid oral
oral dosage
estradiol
forms containing
Prior art date
Application number
GT200500315A
Other languages
English (en)
Spanish (es)
Inventor
Kristina Muller
Torsten Wagner
Adrian Funke
Christian Zurth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500315A publication Critical patent/GT200500315A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
GT200500315A 2004-11-02 2005-10-31 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol GT200500315A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
GT200500315A true GT200500315A (es) 2006-06-06

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500315A GT200500315A (es) 2004-11-02 2005-10-31 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Country Status (21)

Country Link
EP (1) EP1814526A2 (enExample)
JP (1) JP2008518895A (enExample)
KR (1) KR20070085558A (enExample)
CN (1) CN101094656A (enExample)
AR (1) AR053650A1 (enExample)
AU (1) AU2005300658A1 (enExample)
BR (1) BRPI0517940A (enExample)
CA (1) CA2585095A1 (enExample)
CR (1) CR9112A (enExample)
CU (1) CU20070094A7 (enExample)
EA (1) EA013262B1 (enExample)
GT (1) GT200500315A (enExample)
IL (1) IL182635A0 (enExample)
MX (1) MX2007005281A (enExample)
NO (1) NO20072704L (enExample)
PA (1) PA8651401A1 (enExample)
PE (1) PE20061126A1 (enExample)
TW (1) TW200621312A (enExample)
UY (1) UY29185A1 (enExample)
WO (1) WO2006048261A2 (enExample)
ZA (1) ZA200705012B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047956A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 발기부전의 치료 및 예방을 위한 약제 조성물
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
ES2533584T3 (es) 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
CN112516149B (zh) * 2020-07-21 2023-07-18 南方医科大学 苯甲酸雌二醇或其药物可接受盐在制备抗冠状病毒的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (enExample) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US7498303B2 (en) * 2000-10-30 2009-03-03 University Of Zuerich GNRH analogues for treatment of urinary incontinence
DK1343508T3 (da) * 2000-12-15 2012-02-27 Novo Nordisk Femcare Ag Anvendelse af et østrogen til fremstilling af en sammensætning, der indeholder østrogen, til behandling af atrofisk vaginitis
FR2823976A1 (fr) * 2001-04-25 2002-10-31 Theramex Nouvelle composition hormonale et son utilisation
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (ja) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 更年期症の予防・治療用経口組成物

Also Published As

Publication number Publication date
CN101094656A (zh) 2007-12-26
EA013262B1 (ru) 2010-04-30
CA2585095A1 (en) 2006-05-11
CU20070094A7 (es) 2009-09-08
BRPI0517940A (pt) 2008-10-21
MX2007005281A (es) 2008-03-11
PA8651401A1 (es) 2006-12-07
CR9112A (es) 2007-11-23
UY29185A1 (es) 2006-05-31
WO2006048261A3 (en) 2006-09-21
JP2008518895A (ja) 2008-06-05
AU2005300658A1 (en) 2006-05-11
PE20061126A1 (es) 2006-11-11
IL182635A0 (en) 2007-07-24
TW200621312A (en) 2006-07-01
AR053650A1 (es) 2007-05-16
NO20072704L (no) 2007-05-29
EP1814526A2 (en) 2007-08-08
WO2006048261A2 (en) 2006-05-11
ZA200705012B (en) 2008-10-29
EA200700979A1 (ru) 2007-10-26
KR20070085558A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
AR109263A2 (es) Composición que comprende moxidectina
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
MX2007016462A (es) Composiciones topicas para tratar la piel.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
UY31780A (es) Fenoxibenzamidas sustituidas
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
CR9112A (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
CL2008000419A1 (es) Uso de una composicion alimenticia para mejorar el bienestar del pez, viabilidad o recuperacion mas rapida, y/o para la prevencion, alivio y/o tratamiento de salmonidos infectados con la enfermedad del pancreas; y composcion alimenticia para salmonid
AR057161A1 (es) Metodos y formas de dosificacion de derivados de benzisoxazol con mejor eficacia
AR061485A1 (es) Composiciones estabilizadas de tetraciclina
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen